Substudy 01A: Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Conditions: Prostatic Neoplasms, Castration-Resistant Interventions: Drug: MK-5684; Drug: Olaparib; Drug: Docetaxel; Drug: Cabazitaxel Sponsors: Merck Sharp& Dohme LLC; Orion Corporation, Orion Pharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials